---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-24-000127"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:04:06.061477+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tarsus Q3 2024: XDEMVY sales $48.1M, net loss narrows to $23.4M

## Summary
- Net product sales of $48.1M in Q3 2024, up from $1.7M in Q3 2023; over 41,400 bottles delivered.
- Net loss of $23.4M ($0.61 per share) compared to $39.1M ($1.28 per share) in Q3 2023.
- Secured the two remaining large Medicare contracts; coverage now extends to >80% of covered lives.
- Appointed Elizabeth Yeu, M.D. as Chief Medical Officer and Katherine Goodrich, M.D. to board.
- Cash and marketable securities of $317.0M as of September 30, 2024.

## SEC filing metadata
- accession: 0001819790-24-000127
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979024000127/0001819790-24-000127-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979024000127/tars-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-24-000127
- JSON: https://secwatch.observer/filing/0001819790-24-000127.json
- Plain text: https://secwatch.observer/filing/0001819790-24-000127.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.